All In Biotech

Drug Trial Radar · NCT07359963

Treatment of Idiopathic Pulmonary Fibrosis (IPF) by REGEND007 Cell Therapy

An Exploratory Clinical Study on the Intravenous Infusion of REGEND007 (Generic Airway Basal Layer Stem Cell Preparation) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF).

Last checked: Nov 20, 2026Latest source record: Jan 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

12

Planned (sponsor's estimate)

Start

Feb 15, 2026

Primary completion

Feb 15, 2027

Study completion Jun 15, 2027

Sponsor

Lead sponsor
Regend TherapeuticsIndustry
Sponsor type
Industry
First posted
Jan 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a prospective, single-arm, dose-escalation exploratory clinical trial to investigate the safety, tolerability and preliminary efficacy of REGEND007 stem cell preparation administered by intravenous infusion in the treatment of idiopathic pulmonary fibrosis (IPF), with a follow-up period of 12 weeks.

Conditions

  • Idiopathic Pulmonary Fibrosis (IPF)

Interventions

  • REGEND007 Cell TherapyBiological

    This study's intravenous infusion dose escalation protocol is based on a 3+3 dose escalation design, with a total of 4 dose groups. Each group included 3 subjects, and the dose is gradually increased until the maximum tolerated dose(MTD) or the maximum administered dose (MAD) is reached.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence and severity of drug-related adverse events (AEs)Time frame: 12 weeks after the administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Fourth Hospital of Zhejiang University School of Medicine

    Yiwu, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.